The feasibility and tolerability of using Inspiratory Muscle Training (IMT) with adults discharged from the hospital with community-acquired pneumonia (CAP) by Pick, H.J. et al.
CASE REPORT
1www.journals.viamedica.pl
Address for correspondence: Mark A Faghy, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom; e-mail: m.faghy@derby.ac.uk 
DOI: 10.5603/ARM.a2021.0002
Received: 26.06.2020
Copyright © 2021 PTChP
ISSN 2451–4934
Harry J Pick1*, Mark A Faghy2*, Gareth Creswell3, Deborah Ashton1, Charlotte E Bolton1, 
Tricia McKeever1, Wei Shen Lim1, Thomas Bewick3
1Nottingham University Hospital NHS Trust, Nottingham City Hospital, United Kingdom 
2University of Derby, Derby, United Kingdom
3University Hospitals of Derby and Burton NHS Foundation Trust, Derby, United Kingdom 
*Authors contributed equally to this work.
The feasibility and tolerability of using inspiratory muscle 
training with adults discharged from the hospital 
with community-acquired pneumonia 
Abstract
Introduction: Patients experience substantial morbidity following discharge from hospital and during recovery from communi-
ty-acquired pneumonia (CAP). Inspiratory muscle training (IMT) has demonstrated improved functional capacity and reduced 
patient-reported symptoms. To date the safety and tolerability of these methods have not been determined in CAP patients re-
covering following hospitalization. Accordingly, this study aimed to assess the safety and tolerability of IMT in adults discharged 
from hospital with CAP.
Material and methods: Participants received an IMT device (POWERbreathe KHP2) and completed 9-weeks IMT training with 
weekly follow-up. Frequency (twice daily) and load (50% PImax) were fixed throughout, but training volume increased incre-
mentally (2-week habituation phase, 7-week training phase). Primary outcomes of interest included IMT safety and tolerability. 
Results: Twenty-two participants were recruited; 16 were male, mean age 55.2 years (range 27.9–77.3). From 1183 possible 
training days, side effects were reported on 15 occasions by 10 individual participants. All reported side-effects were assessed 
as grade 1 and did not prevent further training. Participant-reported IMT acceptability was 99.4%.
Conclusion: Inspiratory muscle training is safe and tolerable in patients following hospitalisation for CAP. Patient satisfaction with 
IMT is high and it is viewed by patients as being helpful in their recovery. Distinguishing CAP-related symptoms and device-related 
side effects is challenging. Symptom prevalence declined during follow-up with concurrent improvements in spirometry observed. 
Further research is required to determine the efficacy of IMT interventions following CAP and other acute respiratory infections.
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Introduction 
CAP is responsible for over 100,000 admis-
sions to hospital each year in England and Wales 
with an incidence of 8 per 1000 adults aged over 
65 [1, 2]. Most hospitalised patients are dis-
charged into the community to recuperate and 
the burden of disease in recovery is substantial, 
with 65.7% of patients re-consulting a primary 
care practitioner, and > 50% of patients failing 
to return to their usual daily activities in the 
4-weeks post-discharge [3]. Whilst the burden of
recovery is extensive the physiological basis for 
recovery remains poorly understood. Previous 
work in this area has demonstrated reduced skel-
etal muscle strength, impaired exercise capacity 
and reduced quality of life following an episode 
of CAP [4]. A potential mechanism is abnormal 
and impaired respiratory muscle function in the 
post-pneumonia period. In healthy volunteers, 
respiratory muscle strength is associated with 
exacerbated dyspnoea and fatigue, heightened 
perceptual discomfort and reduced exercise ca-
pacity and functional status. During ventilation, 
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breathing accounts for 1–3% of total oxygen con-
sumption and quiet breathing requires a small 
fraction of the respiratory muscles maximal 
pressure generating capacity in healthy indi-
viduals. However, in an acutely diseased lung 
(i.e. CAP) the pressure required to breathe is 
increased due to changes in airway resistance 
and chest wall mechanics [5]. 
Inspiratory muscle training (IMT) improves 
respiratory muscle strength and reduces mark-
ers of physiological stress [6]. IMT techniques 
have also been demonstrated in patient groups; 
reducing dyspnoea perception and discomfort 
in chronic obstructive pulmonary disease, in-
creased strength and endurance of respiratory 
muscles in patients after a cerebrovascular event 
and increased lung volumes, respiratory muscle 
strength, and exercise capacity in elderly patients 
[7, 8]. The efficacy and tolerability of IMT in CAP 
patients have yet to be determined. 
Material and methods
We undertook a prospective observational 
feasibility study with adult patients discharged 
from hospital with CAP. CAP was defined as: the 
presence of one or more symptom of acute low-
er-respiratory respiratory-tract infection (cough, 
increasing breathlessness, sputum production, 
chest pain, and fever); evidence of acute infil-
trates consistent with a respiratory infection on 
admission plain chest radiograph; , and treated 
by the clinical team for CAP. Exclusion criteria 
included; inability to understand verbal or writ-
ten information in English, hospital admission 
within preceding 10 days, active tuberculosis, 
post-obstructive pneumonia secondary to lung 
cancer, aspiration pneumonia, World Health Or-
ganisation performance status 2 or greater prior to 
admission, inability to provide informed consent, 
or presence of a contraindication to pulmonary 
function testing.
Following ethics approval (Ethics reference 
17/EE/0043) and informed consent, twenty-two 
adults (average age was 55.2 years; range: 27.9–
77.3 years, mean CAP score 44.3 ± 19.6) and 
16 (72.7%) males were recruited to the study and 
completed 9 weeks of IMT training (described 
below). One or more co-morbid illness was pres-
ent in 10 patients. World Health Organisation 
(WHO) performance status at hospital admission 
was grade 1 in nine, grade 2 in three, grade 3 in 
seven, and grade 4 in three patients. A control 
group was not included within the study design as 
the primary aim was to determine the safety and 
tolerability of IMT methods in patients following 
hospitalisation for CAP. Most patients (21/22) 
were admitted from the Emergency Department, 
with three patients taking prescribed antibiotics 
before admission. Unilobar consolidation was 
the most common radiographic abnormality 
identified following admission (17/22 patients), 
followed by multilobar consolidation (4/22) and 
unilateral pleural effusion (1/22).
Following informed consent and alongside 
routine clinical investigations, patients were 
assessed for symptom prevalence and functional 
activity weekly for 9 weeks using a combination of 
hospital review, telephone consultation, and pa-
tient diaries. A five-item, CAP specific question-
naire was used to record patient-reported symp-
toms prior to discharge and at each follow-up 
consultation, scoring was conducted inline with 
previous guidelines [9]. Dynamic spirometry 
(forced expiratory volume in 1 second; FEV1 and 
Forced Vital Capacity; FVC) was assessed using 
a handheld spirometer (MicroPlus; Micro Med-
ical, Buckinghamshire, UK) in accordance with 
published guidelines [10]. A hand-held mouth 
pressure meter (Micro R.P.M., Micro Medical, 
Buckinghamshire, UK) was used to assess both 
maximal inspiratory (MIP) and maximal expirato-
ry (MEP) mouth pressure. Patients were provided 
with an IMT device (Figure 1, POWERbreatheK-
HP2, HaB International, Southam, UK) for nine 
weeks. Patients conducted two IMT sessions at 
home each day an intensity equivalent to 50% of 
the participant’s maximum inspiratory muscle 
pressure (MIP). Participants were trained on using 
the device and completing sessions effectively 
Figure 1. A visual representation of the POWERbreatheKHP2 device 
that was used by patients as part of the 9-week intervention
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was conducted at baseline and during all face 
follow up sessions. 
Session volume was incremental and started 
with 10 breaths per session in week one, increas-
ing to 20 breaths in week two, and 30 breaths 
for week’s three to nine.  Patients were asked 
to self-report symptom prevalence and func-
tional activity during weekly phone calls for 
9 weeks, whilst assessments of respiratory muscle 
strength and lung function were conducted using 
standardised ATS/ERS guidelines at discharge, 
6-weeks, and 9-weeks. Adherence to the proto-
col was also confirmed at face to face visits via 
completed participant diaries and verified against 
recorded training sessions on the device. 
Safety was assessed by recording the fre-
quency and severity of patient-reported IMT side 
effects during face to face and weekly telephone 
consultations. IMT tolerability was measured by 
the proportion of patients who completed IMT 
training according to the study protocol. Second-
ary outcomes included changes ion patient-re-
ported symptoms over the study period (CAP 
score) and markers of pulmonary (FEV1, FVC, 
FEV1/FVC, PEF) and respiratory muscle function 
(MIP and MEP). Paired t-tests were used to test the 
significance of the difference between means at 
baseline and follow-up. Statistical analyses were 
conducted using Stata/IC 15 (©StataCorp. 2017). 
Results 
One unexpected and unrelated serious ad-
verse event (death) occurred during study fol-
low-up. Three other participants under active 
follow-up at the time of this adverse event were 
asked to stop further IMT whilst awaiting results 
of an initial internal and additional independent 
external investigation, as directed by the study 
sponsor. Subsequently, these participants did not 
restart IMT as they were outside of the training 
window at the time of conclusion of the inves-
tigation. They were subsequently excluded from 
the analysis of protocol compliance. 
IMT was completed according to protocol 
in 14/19 (73.7% of patients). Side effects from 
IMT were reported on 15 occasions (10 individ-
uals) over a total of 1183 training days (range 
of training days 7 to 63). Side effects related to 
IMT included chest pain (n = 2), cough (n = 1), 
increased dyspnoea (n = 4), and dizziness (n = 
8). Participants rated these side effects as grade 
1 on the Common Terminology Criteria for Ad-
verse Events (CTCAE) scale and it did not prevent 
patients from completing the current session or 
continuing with future training. CAP symptom 
scores improved between discharge (mean 44.3 ± 
19.6) and 9 weeks after discharge (mean 88.2 ± 
15.0), with a significant average improvement of 
43.9 (difference between means, 95% CI: 34.8–
52.9, p < 0.001). All spirometric measures and 
respiratory muscle strength measures improved 
between baseline assessment at discharge and 
repeat assessment at 9-weeks (Table 1). Sixteen 
patients had a repeat chest x-ray within 9-weeks 
of discharge, with complete radiographic resolu-
tion in 14, persistent consolidation in one patient, 
and a unilateral pleural effusion in another. 
Discussion
This is the first study of IMT in adult patients 
recovering following hospitalisation with an 
episode of CAP. We report that IMT is safe and 
tolerable in this patient group, but acknowledge 
the need for further study in this area to determine 
the full extent of any clinical benefits of using 
IMT methods during recovery (i.e. with the use of 
a control group and randomised control design). 
The primary outcome of this work was to 
determine whether IMT methods are safe and 
tolerable to patients during their recovery from 




(n =  20)
9-week follow-up 
(n = 19)
Difference in mean between hospital 
discharge and 9-week follow-up (95% CI)
P value
FEV1  (l) 1.89 2.68 2.73 0.84 (0.54–1.14) < 0.001
FVC (l) 2.27 3.22 3.18 0.91 (0.56–1.27) < 0.001
MIP (cmH2O) 65.2 102.9 116.0 50.8 (37.7–64.0) < 0.001
MEP (cmH2O) 74.4 100.8 105.6 31.2 (18.0–44.4) < 0.001
CAP score (AU) 44.3 83.2 92.8 48.5 (30.2–69.8) < 0.001
CI — confidence interval; FEV1 — forced expiratory volume in 1 second; FVC — forced vital capacity; MIP — mouth maximal inspiratory pressure; MEP — mouth 
maximal expiratory pressure. P-value compares the difference in means at discharge versus 9 weeks
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CAP. This study demonstrates that IMT in adult 
patients recovering following hospitalisation 
with CAP is safe and tolerable. We also observed 
improvement in CAP-symptom scores and lung 
function tests as would be expected in recovery. 
The authors acknowledge that the efficacy of IMT 
methods cannot be determined by this study and 
the full extent to which IMT may have influenced 
the rate or extent of improvement in recovery 
due to the lack of a control group and should be 
considered with future research. Specifically, the 
use of IMT methods needs to be evaluated against 
the low-grade side-effects experienced by patients 
and the protocol adherence to determine the full 
extent of the benefits to patients. 
We do present the first study that demon-
strates that IMT methods are safe and well toler-
ated by patients following admission to hospital 
with CAP. Reported side-effects were rare and 
of low severity, rated as grade 1 on Common 
Terminology Criteria for Adverse Events scale 
(CTCAE), and did not prevent further training 
or deviation from the study protocol. This is 
consistent with results from a study of IMT in 
patients with thoracic malignancy which reported 
IMT-related side effects in only 3 patients during 
follow-up whilst 2 studies of IMT in differing 
patient cohorts (pre-operative IMT in patients 
undergoing coronary artery bypass grafting and 
IMT in chronic heart failure) both reported no 
adverse events during or after IMT. On repeated 
assessment patients reported that they believed 
IMT was helpful in their recovery. This is con-
sistent with results of IMT from other studies; 
pre-operative patients and patients with chronic 
heart failure participating in rehabilitation also 
reported that IMT was tolerable and that they 
believed it to be beneficial in their recovery [11]
FEV1, 24 +/- 7% predicted.
It is plausible that IMT methods could also 
have important implications for patients during 
their recovery from COVID-19 [12]. COVID-19 and 
other viral infections can cause significant dam-
age to the lungs and airways result in acute re-
spiratory distress syndrome (ARDS). The patients 
at the greatest risk are likely to have multiple 
co-morbidities, de-conditioning of the respira-
tory musculature and increased likelihood of 
respiratory failure and the need for critical care 
interventions. Those that develop severe compli-
cations from are admitted to intensive care units 
and require prolonged periods of ventilation. 
Mechanical ventilation induces rapid atrophy 
and profound weakness of the respiratory muscu-
lature (<18 hours), creating a disparity between 
the force-generating capability of the respiratory 
muscles and the pressures required for spon-
taneous tidal breathing [13]. Interventions that 
increase respiratory muscle strength are well 
tolerated by patients with respiratory illness and 
the data here demonstrates that the inclusion of 
IMT techniques could prove a useful addition to 
the recovery from respiratory infections.
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